A new co-operative group: the European Myeloma Network Trialist Group DOI: 10.1080/10428190903191874 Publication date: October 2009 Read More
Autologous Haematopoietic Stem-Cell Transplantation Versus Bortezomib-Melphalan-Prednisone, With or Without Bortezomib-Lenalidomide-Dexamethasone Consolidation Therapy, and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma (EMN02/HO95): A Multicentre, Randomised, Open-Label, Phase 3 Study Main author: Cavo DOI: 10.1016/S2352-3026(20)30099-5 Publication date: June 2020 Connected Trials: EMN02 Read More
Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA) Main author: Bringhen DOI: 10.3324/haematol.2018.191288 Publication date: September 2018 Read More
Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma: A Consensus Statement From The European Myeloma Network Main author: Moreau DOI: 10.3324/haematol.2019.224204 Publication date: December 2019 Read More
Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network. Main author: Cook DOI: 10.1038/s41375-020-0918-6 Publication date: June 2020 Read More
European Myeloma Network guidelines for the management of multiple myeloma-related complications Main author: Terpos DOI: 10.3324/haematol.2014.117176 Publication date: January 2015 Read More
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias Main author: Gavriatopoulou DOI: 10.1038/s41375-018-0209-7 Publication date: September 2018 Read More
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma Main author: Engelhardt DOI: 10.3324/haematol.2013.099358 Publication date: January 2014 Read More
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when Main author: Caers DOI: 10.3324/haematol.2018.189159 Publication date: November 2018 Read More
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. Main author: Engelhardt DOI: 10.3109/10428194.2010.516378 Publication date: January 2010 Read More
European myeloma network: the value of collaborative research Main author: Sonneveld DOI: 10.1159/000087039 Publication date: January 2005 Read More
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives Main author: Gay DOI: 10.3324/haematol.2017.174573 Publication date: February 2018 Read More
Insights on Multiple Myeloma Treatment Strategies Main author: Mateos DOI: 10.1097/HS9.0000000000000163 Publication date: December 2018 Read More
Lenalidomide Maintenance With or Without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis Main author: Bonello DOI: 10.3390/cancers11111735 Publication date: November 2019 Connected Trials: EMN01 Read More
Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis. Main author: Gay DOI: 10.1001/jamaoncol.2018.2961 Publication date: October 2018 Read More
Management of Patients With Multiple Myeloma in the Era of COVID-19 Pandemic: A Consensus Paper From the European Myeloma Network (EMN) Main author: Terpos DOI: 10.1038/s41375-020-0876-z Publication date: May 2020 Read More
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN) Main author: Terpos DOI: https://doi.org/10.1038/s41375-020-0876-z Publication date: May 2020 Read More
Minimal Residual Disease by Flow Cytometry and Allelic-Specific Oligonucleotide Real-Time Quantitative Polymerase Chain Reaction in Patients With Myeloma Receiving Lenalidomide Maintenance: A Pooled Analysis Main author: Gambella DOI: 10.1002/cncr.31854 Publication date: March 2019 Connected Trials: EMN02 Read More
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study Main author: Bringhen DOI: 10.1038/s41375-018-0024-1 Publication date: January 2018 Connected Trials: EMN07 Read More
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement Main author: Dimopoulos DOI: 10.1038/leu.2011.3. Publication date: January 2011 Read More
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) Main author: Larocca DOI: 10.1038/s41375-018-0142-9 Publication date: January 2018 Read More
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN) Main author: Palumbo DOI: 10.1182/blood-2011-06-358812 Publication date: January 2011 Read More
Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. Main author: Sonneveld DOI: 10.1182/blood-2014-05-576256. Publication date: January 2015 Read More
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network Main author: Ludwig DOI: 10.1038/leu.2017.353 Publication date: January 2017 Read More
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network Main author: Ludwig DOI: 10.1038/s41375-018-0040-1 Publication date: January 2018 Read More